Table 2.
Demographics and pre-operative symptoms.
| References | Transcranial approach category | Size (n) | Demographics | Mean follow-up (months) | Tumor volume (cm3) | Pre-operative symptoms | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | Females | Anosmia | Visual issues | Headache | Seizure | Behavioral abnormality | Fatigue | |||||
| Patel et al. (12) | B | 48 | 62 | 36 | 59 | 49 | 18 | 18 | 17 | 11 | 24 | 0 |
| Xu et al. (13) | B | 29 | 55 | 18 | 40 | 43 | 17 | 6 | 0 | 4 | 15 | 0 |
| Farooq et al. (14) | B | 19 | 51 | 18 | 60 | 113 | 11 | 15 | 15 | 0 | 13 | 0 |
| Liu et al. (15) | B | 15 | 52 | 10 | 14.5 | 92 | 0 | 4 | 3 | 2 | 2 | 0 |
| Guduk et al. (2) | U | 61 | 58 | 43 | N/A | 62 | 9 | 14 | 16 | 6 | 9 | 0 |
| Barzaghi et al. (16) | B | 21 | 54 | 12 | 87 | 51 | 11 | 8 | 0 | 3 | 8 | 0 |
| Nanda et al. (17) | B/U | 16/41 | 55/60 | 7/27 | 59.6 | N/A | 9/21 | 6/16 | 8/25 | 2/5 | 8/17 | 6/14 |
| de Alemeida et al. (18) | B | 10 | 50 | 8 | N/A | 36 | N/A | N/A | N/A | N/A | N/A | N/A |
| Pallini et al. (8)* | B/U | 81/18 | 57 | 52/12 | 103 | 67/70 | 59 | 46 | 38 | 19 | 35 | 0 |
| Mielke et al. (3) | U | 43 | 62 | 27 | N/A | N/A | 27 | 14 | 0 | 0 | 22 | 0 |
| Refaat et al. (19) | B/U | 8/6 | 54/47 | 6/5 | N/A | 134/69 | 4/3 | 4/3 | 6/5 | 0/1 | 2/2 | 0/0 |
| Bitter et al. (20) | U | 61 | 60 | 40 | 122 | N/A | 30 | 22 | 18 | 5 | 16 | 3 |
| Jang et al. (21) | B/U | 19/21 | 55/53 | 7/10 | 58 | 60.1/41.6 | 17/12 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 |
| Musluman et al. (22) | U | 42 | 59 | 24 | 52 | N/A | 19 | 23 | 37 | 10 | 28 | 0 |
| Tomasello et al. (23) | U | 18 | 59 | 12 | 93.5 | 23 | 18 | 13 | 13 | 2 | 18 | 0 |
| Pepper et al. (24) | B | 19 | 51 | 8 | N/A | 96 | 1 | 5 | 8 | 1 | 6 | 2 |
| El-Bahy et al. (25) | U | 18 | 49 | 10 | 31 | 34 | 13 | 5 | 18 | 3 | 8 | 0 |
| Aguiar et al. (26) | B/U | 7/14 | 55.5 | 15 | 50 | 41.6 | 21 | 8 | 12 | 5 | 4 | 0 |
| Romani et al. (4) | U | 66 | 57 | 38 | 45 | 54 | 38 | 22 | 11 | 14 | 33 | 0 |
| Gazzeri et al. (27) | B | 36 | 56 | 24 | 111 | 137 | 30 | 20 | 18 | 10 | 25 | 0 |
| Colli et al. (28) | B | 17 | 53 | 16 | 51 | N/A | 5 | 0 | 11 | 5 | 0 | 0 |
| Nakamura et al. (7)* | B/U | 46/36 | 58 | 63 | 63.4 | 61/38 | 48 | 20 | 26 | 16 | 59 | 0 |
| Spektor et al. (5)* | B/U | 47/34 | 55 | 58 | 89/71 | 48/47 | 47 | 22 | 41 | 9 | 21 | 0 |
| Paterniti et al. (29) | U | 20 | 49 | 15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Turazzi et al. (30) | U | 37 | N/A | N/A | 48 | 99 | 27 | 16 | 0 | 0 | 27 | 0 |
| Tsikoudas et al. (31) | B | 13 | 60 | 10 | N/A | 113 | 4 | 5 | 8 | 2 | 8 | 1 |
| Mayfrank et al. (32) | U | 18 | N/A | 13 | N/A | 18 | 11 | 4 | 0 | 1 | 10 | 0 |
*
Not used in pre-operative symptom calculations because the values were not differentiated between approach categories.